H.U. Group Holdings, Inc.

Equities

4544

JP3822000000

Healthcare Facilities & Services

Market Closed - Japan Exchange Other stock markets 11:30:00 28/06/2024 am IST			5-day change	1st Jan Change
2,349 ^JPY	+1.29%		-0.23%	-11.81%

11/06	H.U. Group Secures Highest Rank at MSCI ESG Rating for Third Straight Year	MT
10/05	H.U. Group Holdings, Inc. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on May 28, 2024; Provides Dividend Guidance for the Second Quarter-End and Fiscal Year Ending March 31, 2025	CI

H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025

May 10, 2024

H.U. Group Holdings, Inc. provided consolidated earnings forecasts for the fiscal year ending March 31, 2025. For the year, the company expected Net sales of JPY 241,000 million, Operating profit of JPY 10,000 million, Profit attributable to owners of parent of JPY 7,000 million and Basic earnings per share of JPY 123.20.

Latest news about H.U. Group Holdings, Inc.

H.U. Group Secures Highest Rank at MSCI ESG Rating for Third Straight Year	11/06	MT
H.U. Group Holdings, Inc. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on May 28, 2024; Provides Dividend Guidance for the Second Quarter-End and Fiscal Year Ending March 31, 2025	10/05	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025	10/05	CI
H.U. Group Cuts Forecasts for Fiscal Year Ended March 31	02/05	MT
H.U. Group Holdings, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	26/04	CI
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Executive Officer	26/04	CI
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Chief Financial Officer	26/04	CI
H.U Unit Fujirebio Diagnostics Partners Beckman Coulter in Neurodegenerative Diseases Field	13/03	MT
Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics	13/03	CI
H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 Plasma Assay for the Fully Automated LUMIPULSE G Immunoassay Systems	22/12	CI
Japanese Shares Rebound After Inflation Data, BoJ Rate Outlook	22/12	MT
H.U. Group to Issue Stock Options to Directors, Employees	22/12	MT
H.U. Group to Grant Share Options to Staff	20/11	MT
H.U. Group Holdings, Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024	09/11	CI
H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index	18/23/18	CI
H.U. Group Holdings' Fiscal Full-Year Profit Falls 47%	17/23/17	MT
H.U. Group Holdings, Inc. Announces Dividend for the Year Ended March 31, 2023, Payable on May 30, 2023; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024	16/23/16	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	16/23/16	CI
H.U. Group Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/23/12	CI
H.U. Group Holdings, Inc. Announces Launch of the Fully Automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests	28/23/28	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2023	10/23/10	CI
H.U. Group Holdings, Inc. Provides Year End Dividend Forecast for the Fiscal Year Ending March 31, 2023	10/23/10	CI
H.U. Group Holdings, Inc. Provides Dividend Guidance for the Second Quarter-End and for the Full Year of Fiscal Year Ending March 31, 2023	15/22/15	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	15/22/15	CI
Japan Equities End Week Higher; W-Scope Zooms 12% on Securing Approval for Unit's Listing in Korea	24/22/24	MT

Chart H.U. Group Holdings, Inc.

Duration

Period

More charts

Company Profile

H.U. Group Holdings Inc, formerly Miraca Holdings Inc is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and sterilization related business. The Company operates in four business segments. The Outsourced Clinical Testing segment accepts special tests from medical institutions. The Clinical Laboratory Medicine segment manufactures and sells clinical laboratory medicines and sells them to medical institutions and contract clinical laboratory companies. The Sterilization segment mainly entrusts the sterilization of medical equipment used for medical treatment in hospitals of large-scale hospitals and the related operations. The New Development & Others segment is involved in the homecare & welfare equipment business, self-medication & health insurance business, food & environment & cosmetics inspection business.

Sector

Healthcare Facilities & Services

Calendar

06/08/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for H.U. Group Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2,349 JPY

Average target price

2,368 JPY

Spread / Average Target

+0.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
H.U. GROUP HOLDINGS, INC.	-11.81%	830M
SONIC HEALTHCARE LIMITED	-18.02%	8.43B
RADNET, INC.	+69.46%	4.35B
DR. LAL PATHLABS LIMITED	+7.88%	2.78B
SYNLAB AG	-1.93%	2.64B
NEOGENOMICS, INC.	-14.28%	1.77B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-56.54%	1.74B
FLEURY S.A.	-16.69%	1.48B
METROPOLIS HEALTHCARE LIMITED	+17.87%	1.22B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-49.60%	1.02B

Medical & Diagnostic Laboratories